Cost of medicines in India - branded, generics and branded generics

References

1. Ministry of Finance, Government Social Sector Spending Shows Rising Trend Since 2016, States Economic Survey 2023-24. Available at: https://pib.gov.in/PressReleasePage. aspx?PRID =2034937#:~:text=11.39%20lakh%20crores%20and%20health,1.9 %25%20in%20the%20same%20period.
2. Mistry N, Venkateswaran S, Baru R, Patel V. Editorial: Realizing universal health coverage in India. Front Public Health. 2023:11:1243676.
3. Reshmi B, Unnikrishnan B, Parsekar SS, Rajwar E, Vijayamma R, Venkatesh BT. Health insurance awareness and its uptake in India: a systematic review protocol. BMJ Open. 2021;11(4):e043122.
4. Roy V, Gupta U, Agarwal AK. Cost of medicines & their affordability in private pharmacies in Delhi (India). Indian J Med Res. 2012;136(5):827-35.
5. Chattopadhyay S. Black money in white coats: whither medical ethics?. Indian J Med Ethics. 2008;5(1):20-1.
6. Chattopadhyay S. Corruption in healthcare and medicine: why should physicians and bioethicists care and what should they do?. Indian J Med Ethics. 2013:10(3):153-9.
7. Arun Babu T, Venkatesh C, Sharmila V. Are tomorrow's doctors aware of the code of medical ethics?. Indian J Med Ethics. 2013;10(3):192-4.
8. Danzon, P.M., Towse, A. Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents. Int J Health Care Fin Econ. 2003;3;183–205
9. Mattew J. Engineering, IP Act, Dramatic Story Of the Indian Pharma Industry: Reverse Engineering, IP Act, Struggle, Leadership, and More., Available at: https://medium.com/@josematteew/dramatic- story-of-the-indian-pharma-industry-reverse-engineering-ip-act- struggle-leadership-51bb046f5553. 2023.
10. Cherian JJ, Rahi M, Singh S, Reddy SE, Gupta YK, Katoch VM, Kumar V, Selvaraj S, Das P, Gangakhedkar RR. India’s Road to Independence in Manufacturing Active Pharmaceutical Ingredients: Focus on Essential. Med Econ. 2021; 9(2):71.
11. Akhtar G. Indian Pharmaceutical Industry: An Overview. IOSR J Hum Soc Sci. 2013;13(3):51-66.
12. MedIndia. net Cetirizine Price of 477 brands. Available at: https://www.medindia.net/drug-price/cetirizine.htm
13. Smith MK, Tickell S. The essential drugs concept is needed now more than ever. Transac Royal Soc Trop Med Hyg. 2003; 97: 2-5.
14. Kar SS, Pradhan HS, Mohanta GP. Concept of essential medicines and rational use in public health. Indian J Commun Med. 2010;35(1):10-3.
15. Committee to Consider High Trade Margins Issue. Report of the Committee 2016. available at: https://pharmaceuticals. gov. 26 Ghooi et al / Indian Journal of Pharmacy and Pharmacology 2025;12(1):18–26 in/sites/default/files/High%20treade%20margin%20report%20and %20latter%20_0.pdf
16. Bhaskarabhatla A. Brief History of Regulating Pharmaceutical Prices. In: Regulating Pharmaceutical Prices in India. India Studies in Business and Economics. Springer, Cham. https:
17. National Pharmaceutical Pricing Authority, The Drugs (Price Control) Order, 2013. Available at: https:// www.nppaindia.nic.in/wp-content/uploads/2018/12/DPCO 2013_03082016.pdf
18. Verghese NR, Barrenetxea J, Bhargava Y, Agrawal S, Finkelstein EA. Government Pharmaceutical Pricing Strategies in the Asia- Pacific Region: An Overview. J Mark Access Health Pol. 2019;7(1):1601060.
19. Ghosh PK. Government’s Policies and Growth of Pharmaceutical Industry in India 1947-2018: A Review. Research and Information Systems for Developing Countries. 2019; Available at: https://ris.org.in/sites/default/files/Publication/DP%20236%20P%2 0K%20Ghosh%20DP-min.pdf
20. National Pharmaceutical Pricing Authority, (2024) S.O. 1574(E). Available at: https://dc.kerala.gov.in/wp-content/uploads /2024/03/NPPA-updated-price-list-AS-ON-28.02.2024.pdf
21. Schumock GT, Vermeulen LC. The Rising Cost of Prescription Drugs: Causes and Solutions. Pharmacotherapy. 2017;37(1):9-11.
22. Rana P, Roy V. Generic medicines: issues and relevance for global health. Fundam Clin Pharmacol. 2015;29(6):529-42.
23. McMullan P, Ajay VS, Srinivas R, Bhalla S, Prabhakaran D, Banerjee A. Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis. Glob Health Action. 2018;11(1):1434935.
24. Singal GL, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Indian J Pharmacol. 2011;43(2):131-6.
25. Das M, Choudhury S, Maity S, Hazra A, Pradhan T, Pal A, Roy RK. Generic versus branded medicines: An observational study among patients with chronic diseases attending a public hospital outpatient department. J Nat Sci Biol Med. 2017;8(1):26-31.
26. Thawani V, Mani A, Upmanyu N. (2017) Why the Jan Aushadhi Scheme Has Lost Its Steam in India? J Pharmacol Pharmacother. 8(3):134-6.
27. Medical Council of India. Code of Medical Ethics Regulations
28. Available at: https://www.nmc.org.in/rules-regulations/code- of-medical-ethics-regulations-2002/
29. Singh R. CDSCO flags substandard batches in over 50 commonly prescribed drugs. Business Standard 26th September 2024.
30. Das S. Pharma industry in a huddle after fresh NMC regulations for doctors. Business Standard, 13 August 2023 Available at: https://www.business-standard.com/industry/news/pharma- industry-in-a-huddle-after-fresh-nmc-regulations-for-doctors- 123081300469_1.html
31. Mishra BK. NMC generics diktat endangers both patients and doctors. The Times of India, 20 August 2023 Available at: https://timesofindia.indiatimes.com/blogs/voices/nmc-generics- diktat-endangers-both-patients-and-doctors/
32. Manzoli L, Flacco ME, Boccia S, D'Andrea E, Panic N, Marzuillo C, Siliquini R, Ricciardi W, Villari P, Ioannidis JP. Generic versus brand-name drugs used in cardiovascular diseases. Eur J Epidemiol. 2016;31(4):351-68.
33. Zaid AN, Abualhasan MN, Watson DG, Mousa A, Ghazal N, Bustami R. Investigation of the bioequivalence of montelukast chewable tablets after a single oral administration using a validated LC-MS/MS method. Drug Des Devel Ther. 2015;23;9:5315-21.
34. Alloway RR, Vinks AA, Fukuda T, Mizuno T, King EC, Zou Y, Jiang W, Woodle ES, Tremblay S, Klawitter J, Klawitter J, Christians U. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. PLoS Med. 2017;14(11):e1002428.
35. Estevez-Carrizo FE, Parrillo S, Ercoli MC, Estevez-Parrillo FT. Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open- label, two-period crossover study in healthy Uruguayan volunteers. Clin Ther. 2011;33(6):738-45.
36. Zaid AN, Al Ramahi R, Bustami R, Mousa A, Khasawneh S. Comparative fasting bioavailability of two clopidogrel formulations in healthy Mediterranean volunteers: an in vitro-in vivo correlation. Drug Des Devel Ther. 24(9)2359-65.
37. Leclerc J, Blais C, Rochette L, Hamel D, Guénette L, Poirier P. Trends in Hospital Visits for Generic and Brand-Name Warfarin Users in Québec, Canada: A Population-Based Time Series Analysis. Am J Cardiovasc Drugs. 2019;19(3):287-97.
38. Estevez-Carrizo FE, Parrillo S, Ercoli MC, Estevez-Parrillo FT. Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open- label, two-period crossover study in healthy Uruguayan volunteers. Clin Ther. 2011;33(6):738-45.
39. Zaid AN, Al Ramahi R, Bustami R, Mousa A, Khasawneh S. Comparative fasting bioavailability of two clopidogrel formulations in healthy Mediterranean volunteers: an in vitro-in vivo correlation. Drug Des Devel Ther. 2015;24(9)2359-65.
40. Leclerc J, Blais C, Rochette L, Hamel D, Guénette L, Poirier P. Trends in Hospital Visits for Generic and Brand-Name Warfarin Users in Québec, Canada: A Population-Based Time Series Analysis. Am J Cardiovasc Drugs. 2019;19(3):287-97.